Stocktoria
Elicio Therapeutics, Inc. ELTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-02-05
Elicio Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $28.3M | $2.9M |
| R&D expense | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M | $39.0M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M | -$55.3M |
| Interest expense | — | — | $1.1M | $3.6M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M | -$80.1M |
| EPS (diluted) | $-2.58 | $-4.25 | $-6.96 | $-89.27 | $-1.93 | $-5.43 |
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M | -$22.9M |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M | -$22.9M |
| Cash & equivalents | $18.6M | $17.6M | $12.9M | $6.2M | $88.8M | $34.6M |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M | $47.3M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M | $137.8M |
| Shareholders' equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M | -$90.4M |
Growth · year-over-year · Revenue CAGR -10.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | -91.9% | +883.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.